Overview
- Peptide CTAENTLFYVKES, corresponding to amino acid residues 270-282 of human P2RY12 (Accession Q9H244). 3rd extracellular loop.
- Rat and mouse brain lysates, rat basophilic leukemia (RBL) and human brain glioblastoma (U-87 MG) cell line lysates (1:400-1:2000).
- Western blot analysis of rat brain lysate (lanes 1 and 3) and mouse brain lysate (lanes 2 and 4):1,2. Guinea pig Anti-P2Y12 Receptor (extracellular) Antibody (#APR-020-GP), (1:400).
3,4. Guinea pig Anti-P2Y12 Receptor (extracellular) Antibody, preincubated with P2Y12 Receptor (extracellular) Blocking Peptide (#BLP-PR020). - Western blot analysis of rat basophilic leukemia (RBL) cell line lysate (lanes 5 and 7) and human brain glioblastoma (U-87 MG) cell line lysate (lanes 6 and 8):5,6. Guinea pig Anti-P2Y12 Receptor (extracellular) Antibody (#APR-020-GP), (1:400).
7,8. Guinea pig Anti-P2Y12 Receptor (extracellular) Antibody, preincubated with P2Y12 Receptor (extracellular) Blocking Peptide (#BLP-PR020).
- Human glioblastoma (U-87 MG) cells (1:100).
The P2Y receptors belong to the G-protein coupled receptor superfamily. They mediate the actions of the extracellular nucleotides (ATP, ADP, UTP and UDPA). Eight functional mammalian P2Y receptors have been described: P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, and the UDP-glucose receptor, now renamed P2Y141-3.
The P2Y12 receptor is co-expressed with P2Y1 receptor on platelets leading to shape change, aggregation, and rise in intracellular Ca2+ upon activation.
The only other expression of P2Y12 was found in brain, according to results of reverse transcription-polymerase chain reaction and northern blotting4. The P2Y12 receptor has become a target for potential therapeutic drugs for the treatment of thromboembolism and other clotting disorders4.